CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sunho Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sunho Biologics Inc
Room 302, Building 3
No. 198 Peninsula Middle Road, Dipu Stre
HUZHOU, ZHJ  China Ticker: 28982898
Business Summary
Sunho Biologics Inc is a clinical stage biopharmaceutical company mainly focusing on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. The Company is also engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board FengZhang 51 7/22/2023 5/14/2021
Chief Executive Officer, Chief Scientific Officer, Executive Director XiaolingJiang 43 1/23/2026 7/21/2023
Chief Executive Officer, Chief Scientific Officer, Executive Director LiusongYin 38 7/22/2023 7/21/2023
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 128 (As of 6/30/2025)
Outstanding Shares: 156,666,800 (As of 6/30/2025)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026